Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.
Shang-Hsuan PengChing-Hung LinI-Chun ChenYing-Chun ShenDwan-Ying ChangTom Wei-Wu ChenShu-Min HuangFu-Chang HuYen-Shen LuPublished in: Cancer medicine (2023)
Compared with non-Asian patients, Asian patients with advanced cancers may derive superior OS benefits from pembrolizumab. Although the results warrant further exploration, this meta-analysis provides insight into clinical research design.